Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

Nature Biotechnology

Volumn 28, Issue 8, 2010, Pages 863-867

  Ghaderi, Darius ^a,b   Taylor, Rachel E ^a   Padler Karavani, Vered ^a   Diaz, Sandra ^a   Varki, Ajit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sialix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINES; CETUXIMAB; CLINICAL USE; COVALENTLY BOUND; CULTURE MEDIUM; DRUG CLEARANCE; DRUG DEVELOPMENT; ERBITUX; HEALTHY HUMANS; HEALTHY INDIVIDUALS; IMMUNE COMPLEX; IMMUNOGENICITY; IN-VITRO; MAMMALIAN CELL LINES; N-GLYCOLYLNEURAMINIC ACID; RECOMBINANT GLYCOPROTEINS; SIALIC ACIDS;

ACIDS; ANIMAL CELL CULTURE; CARBOXYLIC ACIDS; GLYCOPROTEINS; LIGANDS; MAMMALS; MONOCLONAL ANTIBODIES; PROTEINS;

CELL CULTURE;

ANTIBODY; CETUXIMAB; DROTRECOGIN; IDURONATE 2 SULFATASE; N GLYCOLOYLNEURAMINIC ACID; NEU5GC ANTIBODY; PANITUMUMAB; SIALIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHINESE HAMSTER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL CULTURE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE; CULTURE MEDIA; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; MICE; N-ACETYLNEURAMINIC ACID; NEURAMINIC ACIDS; RECOMBINANT PROTEINS;

ANIMALIA; MAMMALIA; MUS;

EID: 77955436442     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1651     Document Type: Article

References (38)

1. Hokke, C.H. et al. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett. 275, 9-14 (1990).
2. Noguchi, A., Mukuria, C.J., Suzuki, E. & Naiki, M. Failure of human immunoresponse to N-glycolylneuraminic acid epitope contained in recombinant human erythropoietin. Nephron 72, 599-603 (1996).
3. Tangvoranuntakul, P. et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. USA 100, 12045-12050 (2003).
4. Padler-Karavani, V. et al. Diversity in specifcity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 18, 818-830 (2008).
5. Aggarwal, S. What′s fueling the biotech engine\2007. Nat. Biotechnol. 26, 1227-1233 (2008).
6. Arnold, J.N., Wormald, M.R., Sim, R.B., Rudd, P.M. & Dwek, R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007).
7. Durocher, Y. & Butler, M. Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 20, 700-707 (2009).
8. Higgins, E. Carbohydrate analysis throughout the development of a protein therapeutic. Glycoconj. J. 27, 211-225 (2009).
9. Galili, U. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation 78, 1093-1098 (2004).
10. Varki, A. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446, 1023-1029 (2007).
11. Bardor, M., Nguyen, D.H., Diaz, S. & Varki, A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 280, 4228-4237 (2005).
12. Borys, M.C. et al. Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol. Bioeng. 105, 1048-1057 (2009).
13. Chung, C.H. et al. Cetuximab-induced anaphylaxis and IgE specifc for galactose-alpha-1,3-galactose. N. Engl. J. Med. 358, 1109-1117 (2008).
14. Delbaldo, C. et al. Pharmacokinetic profle of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur. J. Cancer 41, 1739-1745 (2005).
15. Saadeh, C.E. & Lee, H.S. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann. Pharmacother. 41, 606-613 (2007).
16. Diaz, S.L. et al. Sensitive and specifc detection of the non-human sialic acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS ONE 4, e4241 (2009).
17. Muchmore, E.A., Milewski, M., Varki, A. & Diaz, S. Biosynthesis of N-glyco-lyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool. J. Biol. Chem. 264, 20216-20223 (1989).
18. Hedlund, M. et al. N-glycolylneuraminic acid defciency in mice: implications for human biology and evolution. Mol. Cell. Biol. 27, 4340-4346 (2007).
19. Hedlund, M., Padler-Karavani, V., Varki, N.M. & Varki, A. Evidence for a human-specifc mechanism for diet and antibody-mediated infammation in carcinoma progression. Proc. Natl. Acad. Sci. USA 105, 18936-18941 (2008).
20. Tahara, H. et al. Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine monophospho-n-acetylneuraminic acid hydroxylase-defcient mice. J. Immunol. 184, 3269-3275 (2010).
21. Taylor, R.E. et al. Novel mechanism for the generation of human xeno-auto-antibodies against the non-human sialic acid N-glycolylneuraminic acid. J. Exp. Med. published online, doi: 10.1084/jem.20100575 (12 July 2010).
22. Qian, J. et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-fight tandem mass spectrometry and sequential enzymatic digestion. Anal. Biochem. 364, 8-18 (2007).
23. Axworthy, D.B. et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 97, 1802-1807 (2000).
24. Pham, T. et al. Evidence for a novel human-specifc xeno-auto-antibody response against vascular endothelium. Blood 114, 5225-5235 (2009).
25. Jahn, E.M. & Schneider, C.K. How to systematically evaluate immunogenicity of therapeutic proteins\regulatory considerations. New Biotechnol. 25, 280-286 (2009).
26. Galili, U. et al. Enhancement of antigen presentation of infuenza virus hemagglutinin by the natural human anti-Gal antibody. Vaccine 14, 321-328 (1996).
27. Benatuil, L. et al. The infuence of natural antibody specifcity on antigen immunogenicity. Eur. J. Immunol. 35, 2638-2647 (2005).
28. Abdel-Motal, U.M., Wigglesworth, K. & Galili, U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 27, 3072-3082 (2009).
29. Koren, E. et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333, 1-9 (2008).
30. Shankar, G., Pendley, C. & Stein, K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555-561 (2007).
31. Wilson, J.M. Medicine. A history lesson for stem cells. Science 324, 727-728 (2009).
32. Martin, M.J., Muotri, A., Gage, F. & Varki, A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11, 228-232 (2005).
33. Martin, M.J., Muotri, A., Gage, F. & Varki, A. Response to Cerdan et al.: Complement targeting of nonhuman sialic acid does not mediate cell death of human embryonic stem cells. Nat. Med. 12, 1115 (2006).
34. Van Hoeyveld, E. & Bossuyt, X. Evaluation of seven commercial ELISA kits compared with the C1q solid-phase binding RIA for detection of circulating immune complexes. Clin. Chem. 46, 283-285 (2000).
35. Campagnari, A.A., Gupta, M.R., Dudas, K.C., Murphy, T.F. & Apicella, M.A. Antigenic diversity of lipooligosaccharides of nontypable Haemophilus infuenzae. Infect. Immun. 55, 882-887 (1987).
36. Greiner, L.L. et al. Nontypeable Haemophilus infuenzae strain 2019 produces a bioflm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans. Infect. Immun. 72, 4249-4260 (2004).
37. Gagneux, P. et al. Proteomic comparison of human and great ape blood plasma reveals conserved glycosylation and differences in thyroid hormone metabolism. Am. J. Phys. Anthropol. 115, 99-109 (2001).
38. Debeire, P., Montreuil, J., Moczar, E., van Halbeek, H. & Vliegenthart, J.F.G. Primary structure of two major glycans of bovine fbrinogen. Eur. J. Biochem. 151, 607-611 (1985).